Efficacy and safety of the anti-PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study
单位：[1]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China[2]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Gynecol Oncol, Union Hosp, Wuhan, Peoples R China华中科技大学同济医学院附属协和医院[3]Henan Tumor Hosp, Zhengzhou, Henan, Peoples R China河南省肿瘤医院[4]Lees Pharmaceut Holdings Ltd, Hong Kong, Peoples R China[5]Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[6]Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China[7]Henan Canc Hosp, Zhenzhou, Peoples R China河南省肿瘤医院[8]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China[9]Chongqing Univ, Canc Hosp, Dept Gynecol Oncol, Chongqing, Peoples R China[10]Fujian Canc Hosp, Fuzhou, Peoples R China[11]Gunangxi Med Univ, Affiliated Tumor Hosp, Guangxi, Peoples R China[12]Oncol Med Univ, Guangxi, Peoples R China[13]Harbin Med Univ, Affiliated Tumor Hosp, Harbin, Peoples R China[14]Yunnan Prov Tumor Hosp, Kun Ming, Peoples R China[15]Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
An Jusheng,Li Guiling,Tang Jie,et al.Efficacy and safety of the anti-PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
An, Jusheng,Li Guiling,Tang, Jie,Li, Benjamin Xiaoyi,Xiong, Hui Hua...&Wu, Lingying.(2022).Efficacy and safety of the anti-PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
An, Jusheng,et al."Efficacy and safety of the anti-PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学